Pharmacogenomics of cytochrome P450 enzymes in tumours

Current Pharmacogenomics

Volumn 2, Issue 3, 2004, Pages 243-254

  Downie, Diane ^a   Rooney, Patrick H ^a   McFadyen, Morag C E ^a   Murray, Graeme I ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Anticancer agent; CYP1B1; Cytochrome P450; Neoplasm; Pharmacogenomics; Polymorphism

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 5 FLUORO 2 (4 LYSYLAMINO 3 METHYLPHENYL)BENZOTHIAZOLE; ANTINEOPLASTIC AGENT; BENZOTHIAZOLE DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 1B1; CYTOCHROME P450 2C; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOTOXIC AGENT; DNA; DNA VACCINE; DOCETAXEL; DRUG METABOLIZING ENZYME; FREE RADICAL; GEMCITABINE; IFOSFAMIDE; NIFEDIPINE; PACLITAXEL; PLASMID DNA; PRODRUG; PROTEIN; RESVERATROL; TETRAMETHOXYSTILBENE; THIOTEPA; UNCLASSIFIED DRUG; ZYC 300;

ASTHMA; BIOTECHNOLOGY; CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE PREDISPOSITION; DNA MICROARRAY; DOSE RESPONSE; DRUG ACTIVATION; DRUG METABOLISM; DRUG PREFERENCE; ENZYME POLYMORPHISM; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENE THERAPY; HUMAN; INDIVIDUALIZATION; METABOLIC REGULATION; MOLECULAR BIOLOGY; MULTIGENE FAMILY; NONVIRAL GENE DELIVERY SYSTEM; PHARMACODYNAMICS; PHARMACOGENOMICS; PREDICTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT PLANNING;

EID: 4444369072     PISSN: 15701603     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570160043377411     Document Type: Review

References (98)

1. Aebersold, R. and Mann, M. (2003) Mass spectrometry-based proteomics. Nature 422, 198-207.
2. Bahadur, N.; Leathart, J. B.; Mutch, E.; Steimel-Crespi, D.; Dunn, S. A.; Gilissen, R.; Houdt, J. V.; Hendrickx, J.; Mannens, G.; Bohets, H.; Williams, F. M.; Armstrong, M.; Crespi, C. L. and Daly, A. K. (2002) CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochem. Pharmacol. 64, 1579-1589.
3. Bailey, L. R.; Roodi, N.; Dupont, W. D. and Parl, F. F. (1998) Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res. 58, 5038-5041.
4. Bohnenstengel, F.; Hofmann, U.; Eichelbaum, M. and Kroemer, H. K. (1996) Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophosphamide in humans. Eur. J. Clin. Pharmacol. 51, 297-301.
5. Bournique, B. and Lemarie, A. (2002) Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro; but acts as an effector of this isozyme. Drug Metab. Dispos. 30, 1149-1152.
6. Bradshaw, T. D.; Wrigley, S.; Shi, D. F.; Schultz, R. J.; Paull, K. D. and Stevens, M. F. (1998) 2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity. Br. J. Cower 77, 745-052.
7. Bradshaw, T. D.; Bibby, M. C.; Double, J. A.; Fichtner, L; Cooper, P. A.; Alley, M. C.; Donohue, S.; Stinson, S. F.; Tomaszewjski, J. E., Sausville, E. A. and Stevens, M. F. (2002) Preclinical evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles. Mol. Cancer Ther. 1, 239-246.
8. Brown, J. M. (2000) Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol. Med. Today 6, 157-162.
9. Bruning, T.; Abel, J.; Koch, B.; Lorenzen, K.; Harth, V.; Donat, S.; Sachinidis, A.; Vetter, H.; Bolt, H. M. and Ko, Y. (1999) Real-time PCR-analysis of the cytochrome P450 1B1 codon 432-polymorphism. Arch. Toxicol. 73, 427-430.
10. Burris, H. A.; III; Moore, M. J.; Andersen, J.; Green, M. R.; Rothenberg, M. L.; Modiano, M. R.; Cripps, M. C.; Portenoy, R. K.; Storniolo, A. M.; Tarassoff, P.; Nelson, R.; Dorr, F. A.; Stephens, C. D. and Von Hoff, D. D. (1997) Improvements in survival and clinical benefit with genicitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413.
11. Chaib, H.; Cockrell, E. K.; Rubin, M. A. and Macoska, J. A. (2001) Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. Neoplasia 3, 43-52.
12. Chang, T. K.; Weber, G. F.; Crespi, C. L. and Waxman, D. J. (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53, 5629-5637.
13. Chang, T. K.; Yu, L.; Goldstein, J. A. and Waxman, D. J. (1997) Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 7, 211-221.
14. Chang, T. K.; Lee, W. B. and Ko, H. H. (2000) Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1. Can. J. Physiol. Pharmacol. 78, 874-881.
15. Chen, L. and Waxman, D. J. (1995) Intratumoural activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 55, 581-589.
16. Chua, M.S.; Kashiyama, E.; Bradshaw, T. D.; Stinson, S. F.; Brantley, E.; Sausville, E. A. and Stevens, M. F. (2000) Role of Cyp1A1 in modulation of antitumour properties of the novel agent 2-(4-amino-3-metllylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res. 60, 5196-5203.
17. Chun, Y. J.; Kim, M. Y. and Guengerich, F. P. (1999) Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem. Biophys. Res. Commun. 262, 20-24.
18. Chun, Y. J.; Kim, S.; Kim, D.; Lee, S. K. and Guengerich, F. P. (2001) A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res. 61, 8164-8170.
19. Dai, D.; Zeldin, D. C.; Blaisdell, J. A.; Chanas, B.; Coulter, S. J.; Ghanayem, B. I. and Goldstein, J. A. (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11, 597-607.
20. Dhaini, H. R.; Thomas, D. G.; Giordano, T. J.; Johnson, T. D.; Biermann, J. S.; Leu, K.; Hollenberg, P. F. and Baker, L. H. (2003) Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J. Clin. Oncol. 21, 2481-2485.
21. Dressman, M. A.; Walz, T. M.; Lavedan, C.; Barnes, L.; Buchholtz, S.; Kwon, I.; Ellis, M. J. and Polymeropoulos, M. H. (2001) Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsies. Pharmacogenomics. J. 1, 135-141.
22. Edwards, R. J.; Adams, D. A.; Watts, P. S.; Davies, D. S. and Boobis, A. R. (1998) Development of a comprehensive panel of antibodies against the major xenobiotic metabolizing forms of cytochrome P450 in humans. Biochem. Pharmacol. 56, 377-387.
23. Estabrook, R. W. (1996) The remarkable P450s: a historical overview of these versatile hemeprotein catalysts. FASEB J. 10, 202-204.
24. Friery, O. P.; Gallagher, R.; Murray, M. M.; Hughes, C. M.; Galligan, E. S.; McIntyre, I. A.; Patterson, L. H.; Hirst,D. G. and McKeown, S. R. (2000) Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine. Br. J. Cancer 82, 1469-1473.
25. Fritsche, E.; Bruning, T.; Jonkmanns, C.; Ko, Y.; Bolt, H. M. and Abel, J. (1999) Detection of cytochrome P450 1B1 Bfr I polymorphism: genotype distribution in healthy German individuals and in patients with colorectal carcinoma. Pharmacogenetics 9, 405-408.
26. Galeva, N.; Yakovlev, D.; Koen, Y.; Duzhak, T. and Alterman, M. (2003) Direct Identification of Cytochrome P450 Isozymes by Matrix-assisted Laser Desorption/Ionization Time of Flight-Based Proteomic Approach. Drug Metab. Dispos. 31, 351-355.
27. Gallagher, R.; Hughes, C. M.; Murray, M. M.; Friery, O. P.; Patterson, L. H.; Hirst, D. G. and McKeown, S. R. (2001) The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br. J. Cancer 85, 625-629.
28. Gibson, P.; Gill, G. H.; Khan, P. A.; Seargent, J. M.; Martin, S. W.; Batman, P. A.; Griffith, J.; Bradley, C. Double, J. A.; Bibby, M. C. and Loadman, P. M. (2003) Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. Mol. Cancer Ther. 2, 527-534.
29. Goldstein, J. A. and de Morais, S. M. (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4, 285-299.
30. Goodman, M. T.; McDuffie, K.; Kolonel, L. N.; Terada, K.; Donlon, T. A.; Wilkens, L. R.; Guo, C. and Le Marchand, L. (2001) Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol. Biomarkers Prev. 10, 209-216.
31. Han, W.; Pentecost, B. T. and Spivack, S. D. (2003) Functional evaluation of novel single nucleotide polymorphisms and haplotypes in the promoter regions of CYP1B1 and CYP1A1 genes. Mol. Carcinogenesis 37, 158-169.
32. Hanna, I. H.; Dawling, S.; Roodi, N.; Guengerich, F. P. and Parl, F, F. (2000) Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res. 60, 3440-3444.
33. Harris, J. W.; Rahman, A.; Kim, B. R.; Guengerich, F. P. and Collins, J. M. (1994) Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54, 4026-4035.
34. Hedley, M. L.; Curley, J. and Urban, R. (1998) Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat. Med. 4, 365-368.
35. Hellmann, G. M.; Fields, W. R. and Doolittle, D. J. (2001) Gene expression profiling of cultured human bronchial epithelial and lung carcinoma cells. Toxicol. Sci. 61, 154-163.
36. Henderson, C. J.; Sahraouei, A. and Wolf, C. R. (2000) Cytochrome P450s and chemoprevention. Biochem. Soc. Trans. 28, 42-46.
37. Hutchinson, I.; Jennings, S. A.; Vishnuvajala, B. R.; Westwell, A. D. and Stevens, M. F. (2002) Antitumour benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumour 2-(4-aminophenyl)benzothiazole amino acid prodrugs. J. Med. Chem. 45, 744-747.
38. Inaba, T. (1990) Phenytoin: pharmacogenetic polymorphism of 4′-hydroxylation. Pharmacol. Ther. 46, 341-347.
39. Ingelman-Sundberg, M. (2001) Implications of polymorphic cytochrome p450-dependent drug metabolism for drug development. Drug Metab. Dispos. 29, 570-573.
40. Inoue, K.; Asao, T. and Shimada, T. (2000) Ethnic-related differences in the frequency distribution of genetic polymorphisms in the CYP1A1 and CYP1B1 genes in Japanese and Caucasian populations. Xenobiotica 30, 285-295.
41. Kan, O.; Kingsman, S. and Naylor, S. (2002) Cytochrome P450-based cancer gene therapy: current status. Expert. Opin. Biol. Ther. 2, 857-868.
42. Kleinbloesem, C. H.; van Brummelen, P.; Faber, H.; Danhof, M.; Vermeulen, N. P. and Breimer, D. D. (1984) Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem. Pharmacol. 33, 3721-3724.
43. Ko, Y.; Abel, J.; Harth, V.; Brode, P., Antony, C.; Donat, S.; Fischer, H. P.; Ortiz-Pallardo, M. E.; Their, R.; Sachinidis, A.; Vetter, H.; Bolt, H. M.; Herberhold, C. and Bruning, T. (2001) Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumour tissue. Cancer Res. 61, 4398-4404.
44. Lamba, J. K.; Lin, Y. S.; Thummel, K.; Daly, A.; Watkins, P. B.; Strom, S.; Zhang, J. and Schuetz, E. G. (2002) Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12, 121-132.
45. Lander, E. S.; Linton, L. M.; Birren, B.; Nusbaum, C.; Zody, M. C.; Baldwin, J.; Devon, K.; Dewar, K.; Doyle, M.; FitzHugh, W.; Funke, R.; Gage, D.; Harris, K.; Heaford, A.; Howland, J.; Kann, L.; Lehoczky, J.; LeVine, R.; McEwan, P.; McKernan, K.; Meldrim, J.; Mesirov, J. P.; Miranda, C.; Morris, W.; Naylor, J.; Raymond, C.; Rosetti, M.; Santos, R.; Sheridan, A.; Sougnez, C.; Stange-Thomann, N.; Stojanovic, N.; Subramanian, A.; Wyman, D.; Rogers, J.; Sulston, J.; Ainscough, R.; Beck, S.; Bentley, D.; Burton, J.; Clee, C.; Carter, N.; Coulson, A.; Deadman, R.; Deloukas, P.; Dunham, A.; Dunham, I; Durbin, R.; French, L.; Grafham, D.; Gregory, S.; Hubbard, T.; Humphray, S.; Hunt, A.; Jones, M.; Lloyd, C.; McMurray, A.; Matthews, L.; Mercer, S.; Milne, S.; Mullikin, J. C.; Mungall, A.; Plumb, R.; Ross, M.; Shownkeen, R.; Sims, S.; Waterston, R. H.; Wilson, R.K.; Hillier, L.W.; McPherson, J. D.; Marra, M. A.; Mardis, E. R.; Fulton, L. A.; Chinwalla, A. T.; Pepin, K. H.; Gish, W. R.; Chissoe, S. L.; Wendl, M. C.; Delehaunty, K. D.; Miner, T. L.; Delehaunty, A.; Kramer, J. B.; Cook, L. L.; Fulton, R. S.; Johnson, D. L.; Minx, P. J.; Clifton, S. W.; Hawkins, T.; Branscomb, E.; Predki, P.; Richardson, P.; Wenning, S.; Slezak T.; Dogget, N.; Cheng, J. F; Olsen, A.; Lucas, S.; Elkin, C.; Uberbacher, E.; et al. (2001) Initial sequencing and analysis of the human genome. Nature 409, 860-921
46. Lazarou, J.; Pomeranz, B. H. and Corey, P. N. (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200-1205.
47. Le Guellec, C.; Lacarelle, B.; Catalin, J. and Durand, A. (1993) Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother. Phamacol. 32, 491-495.
48. Lenigk, R.; Liu, R. H.; Athavale, M.; Chen, Z.; Ganser, D.; Yang, J.; Rauch, C.; Liu, Y.; Chan, B.; Yu, H.; Ray, M.; Marrero, R. and Grodzinski, P. (2002) Plastic biochannel hybridization devices: a new concept for microfluidic DNA arrays. Anal. Biochem. 311, 40-49.
49. Lennon, G. G. (2000) High-throughput gene expression analysis for drug discovery. Drug Discov. Today 5, 59-66.
50. Lewis, D. F.; Gillam, E. M.; Everett, S. A. and Shimada, T. (2003) Molecular modelling of human CYP1B1 substrate interactions and investigation of allelic variant effects on metabolism. Chem. Biol. Interact. 145, 281-295.
51. Loaiza-Perez, A. I.; Trapani, V.; Hose, C.; Singh, S. S.; Trepel, J. B.; Stevens, M. F.; Bradshaw, T. D. and Sausville, E. A. (2002) Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumour agent 2-(4-amino-3-methylphenyl) benzothiazole. Mol. Pharmacol. 61, 13-19.
52. Lohr, M.; Hoffmeyer, A.; Kroger, J.; Freund, M.; Hain, J.; Holle, A.; Karle, P.; Knofel, W. T.; Liebe, S.; Muller, P.; Nizze, H.; Renner, M.; Saller, R. M., Wagner, T.; Hauenstein, K.; Gunzburg, W. H. and Salmons, B. (2001) Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 357, 1591-1592.
53. Ma, Q. (2001) Induction of CYP1A1. The AhR/DRE paradigm: transcription, receptor regulation, and expanding biological roles. Curr. Drug Metab. 2, 149-164.
54. Macgregor, P.F. (2003) Gene expression in cancer: the application of microarrays. Expert. Rev. Mol. Diagn. 3, 185-200.
55. Maecker, B.; Sherr, D. H.; Vonderheide, R. H.; von Bergwelt-Baildon, M. S.; Hirano, N.; Anderson, K. S.; Xia, Z.; Butler, M. O.; Wucherpfennig, K. W.; O'Hara, C.; Cole, G.; Kwak, S. S.; Ramstedt, U.; Tomlinson, A. J.; Chicz, R. M.; Nadler, L. M. and Schultze, J. L. (2003) The shared tumour-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 102, 3287-3294.
56. Mancinelli, L.; Cronin, M. and Sadee, W. (2000) Pharmacogenomics: the promise of personalized medicine. AAPS. Pharm. Sci. 2, E4.
57. Marez, D.; Legrand, M.; Sabbagh, N.; Guidice, J. M.; Spire, C.; Lafitte, J. J.; Meyer, U. A. and Broly, F. (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7, 193-202.
58. McCarthy, H. O.; Yakkundi, A.; McErlane, V.; Hughes, C. M.; Keilty, G.; Murray, M.; Patterson, L. H.; Hirst, D. G.; McKeown, S. R. and Robson, T. (2003) Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther. 10, 40-48.
59. McFadyen, M. C.; Breeman, S.; Payne, S.; Stirk, C.; Miller, I. D.; Melvin, W. T. and Murray, G. I. (1999) Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J. Histochem. Cytochem. 47, 1457-1464.
60. McFadyen, M. C.; Cruickshank, M. E.; Miller, I. D.; McLeod, H. L.; Melvin, W. T.; Haites, N. E.; Parkin, D. and Murray, G.I. (2001a) Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br. J. Cancer 85, 242-246.
61. McFadyen, M. C.; McLeod, H. L.; Jackson, F. C.; Melvin, W. T.; Doehmer, J. and Murray, G. I. (2001b) Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem. Pharmacol. 62, 207-212.
62. McFadyen, M. C.; Rooney, P. H.; Melvin, W. T. and Murray, G. I. (2003) Quantitative analysis of the Ah receptor/cytochrome P450 CYP1B1/CYP1A1 signalling pathway. Biochem. Pharmacol. 65, 1663-1674.
63. McKeown, S. R.; Friery, O. P.; McIntyre, I. A.; Hejmadi, M. V.; Patterson, L. H. and Hirst, D. G. (1996) Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. Br. J. Cancer 27; S39-S42.
64. Murray, G. I.; Taylor, M. C.; McFadyen, M. C.; McKay, J. A.; Greenlee, W. F.; Burke, M. D. and Melvin, W. T. (1997) Tumour-specific expression of cytochrome P450 CYP1B1. Cancer Res. 57, 3026-3031.
65. Murray, G. I. (2000) The role of cytochrome P450 in tumour development and progression and its potential in therapy. J. Pathol. 192, 419-426.
66. Nam, K. A.; Kim, S.; Heo, Y. H. and Lee, S. K. (2001) Resveratrol analog, 3,5;2′,4′-tetramethoxy-trans-stilbene, potentiates the inhibition of cell growth and induces apoptosis in human cancer cells. Arch. Pharm. Res. 24, 441-445.
67. Nelson, D. R. (2002). Introductory remarks on human CYPs. Drug Metab. Rev. 34, 1-15. http://drnelson.utmem.edu/human.P450.tab]e.html (accessed July 18, 2003).
68. Pardoll, D. M. and Beckerleg, A.M. (1995) Exposing the immunology of naked DNA vaccines. Immunity 3, 165-169.
69. Patterson, L. H. (1993) Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev. 12, 119-134.
70. Patterson, L. H.; McKeown, S. R.; Robson, T.; Gallagher, R.; Raleigh, S. M. and Orr, S. (1999) Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des. 14 473-486.
71. Patterson, L. H.; McKeown, S. R.; Ruparelia, K.; Double, J. A.; Bibby, M. C.; Cole, S. and Stratford, I. J. (2000) Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br. J. Cancer 82, 1910-1990.
72. Patterson, L. H. and Murray, G. I. (2002) Tumour cytochrome P450 and drug activation. Curr. Pharm. Des. 8, 1335-1347.
73. Paulussen, A.; Lavrijsen, K.; Bohets, H.; Hendrickx, J.; Verhasselt, P.; Luyten, W.; Konings, F. and Armstrong, M. (2000) Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 10, 415-424.
74. Plant, N. J. and Gibson, G. G. (2003) Evaluation of the toxicological relevance of CYP3A4 induction. Curr. Opin. Drug Discov. Devel. 6, 50-56.
75. Rahman, A.; Korzekwa, K. R.; Grogan, J.; Gonzalez, F. J. and Harris, J. W. (1994) Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54, 5543-5546.
76. Raleigh, S. M.; Wanogho, E.; Burke, M. D.; McKeown, S. R. and Patterson, L. H. (1998) Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. Int. J. Radiat. Oncol. Biol. Phys. 42, 763-767.
77. Relling, M. V.; Evans, W. E.; Fonne-Pfister, R. and Meyer, U. A. (1989) Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes. Cancer Res. 49, 68-71.
78. Rochat, B.; Morsman, J. M.; Murray, G.I.; Figg, W. D. and McLeod, H, L. (2001) Human CYP1B1 and anticancer agent metabolism: mechanism for tumour-specific drug inactivation? J. Pharmacol. Exp. Ther. 296, 537-541.
79. Rooney, P. H.; Stevenson, D. A.; Marsh, S.; Johnston, P. G,; Haites, N. E.; Cassidy, J. and McLeod, H. L. (1998) Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors. Cancer Res. 58, 5042-5045.
80. Royer, I.; Monsarrat, B.; Sonnier, M.; Wright, M. and Cresteil, T. (1996) Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res. 56, 58-65.
81. Rylander-Rudqvist, T.; Wedren, S.; Granath, F.; Humphreys, K.; Ahlberg, S.; Weiderpass, E.; Oscarson, M.; Ingelman-Sunberg, M. and Perssn, I. (2003) Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. Carcinogenesis 24, 1533-1539.
82. Shi, D. F.; Bradshaw, T. D.; Wrigley, S.; McCall, C. J.; Lelieveld, P.; Fichtner, I. and Stevens, M. F (1996) Antitumour benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazo1es and evaluation of their activities against breast cancer cell lines in vitro and in vivo. J. Med. Chem. 39, 3375-3384.
83. Shi, M. M. (2001) Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies. Clin. Chem. 47, 164-172.
84. Shimada, T.; Watanabe, J.; Kawajiri, K.; Sutter, T. R.; Guengerich, F. R; Gillam, E. M. and Inoue, K. (1999) Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 20, 1607-1613.
85. Sonnichsen, D. S.; Liu, Q.; Schuetz, E. G.; Schuetz, J. D.; Pappo, A. and Relling, M. V. (1995) Variability in human cytochrome P450 paclitaxel metabolism. J. Pharmacol. Exp. Ther. 275, 566-575.
86. Soyama, A.; Saito, Y.; Hanioka, N.; Murayama, N.; Nakajima, O.; Katori, N.; Ishida, S.; Sai, K.; Ozawa, S. and Sawada, J. I. (2001) Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol. Pharm. Bull. 24, 1427-1430.
87. Stoilov, I; Akarsu, A. N.; Alozie, I.; Child, A.; Barsoum-Homsy, M.; Turacli M. E.; Or, M.; Lewis, R. A.; Ozdemir, N.; Brice, G.; Aktan, S. G.; Chevrette, L.; Coco-Prados, M. and Sarfarazi, M. (1998) Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disruption either the hinge region or the conserved core structures of cytochrome P4501B1. Am. J. Hum. Genet. 62, 573-584.
88. Sullivan-Klose, T. H.; Ghanayeni, B. I.; Bell, D. A.; Zhang, Z. Y.; Kaminsky, L. S.; Shenfield, G. M.; Miners, J.O.; Birkett, D.J. and Goldstein, J.A. (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6, 341-349.
89. Sutter, T. R.; Tang, Y. M.; Hayes C. L.; Wo, Y. Y.; Jabs, E. W.; Li, X.; Yin, H.; Cody, C. W. and Greenlee, W. F. (1994) Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J. Biol. Chem. 269, 13092-13099.
90. Tanaka, Y.; Sasaki, M.; Kaneuchi, M.; Shiina, H.; Igawa, M. and Dahiya, R. (2002) Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem. Biophys. Res. Commun. 296, 820-826.
91. Tang, Y. M.; Green, B. L.; Chen, G.F.; Thompson, P. A.; Lang, N. P.; Shinde, A.; Lin, D. X.; Tan, W.; Lyn-Cook, B. D.; Hammons, G. J. and Kadlubar, F. F. (2000) Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans; Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 10, 761-766.
92. Toide, K.; Yamazaki, H.; Nagashima, R.; Itoh, K.; Iwano, S.; Takahashi, Y.; Watanabe, S. and Kamataki, T. (2003) Aryl hydrocarbon hydroxylase represents CYP1B1, and not CYP1A1, in human fresh isolated white cells: trimordal distribution of japanese population according to induction of CYP1B1 mRNA by environmental dioxins. Cancer Epidemiology, Biomarkers & Prevention 12, 219-222.
93. Venter, J. C.; Adams, M. D.; Myers, E. W.; Li, P. W.; Mural, R. J.; Sutton, G. G.; Smith, H. O.; Yandell, M.; Evans, C. A.; Holt, R. A.; Gocayne, J. D.; Amanatides, P.; Ballew, R. M.; Huson, D. H.; Wortman, J. R.; Zhang, Q.; Kodira, C. D.; Zheng, X. H.; Chen, L.; Skupski, M.; Subramanian, G.; Thomas, P. D.; Zhang, J.; Gabor Miklos, G. L.; Nelson, C.; Broder, S.; Clark, A. G.; Nadeau, J.; McKusick, V. A.; Zinder, N.; Levine, A. J.; Roberts, R. J.; Simon, M.; Slayman, C.; Hunkapiller, M.; Bolanos, R.; Delcher, A.; Dew, I.; Fasulo, D.; Flanigan, M.; Florea, L.; Halpern, A.; Hannenhalli, S.; Kravitz, S.; Levy, S.; Mobarry, C.; Reinert, K.; Remington, K.; Abu-Threideh, J.; Beasley, E.; Biddick, K.; Bonazzi, V.; Brandon, R.; Cargill, M.; Chandramouliswaran, L; Charlab, R.; Chaturvedi, K.; Deng, Z.; Di, F.; V; Dunn, P.; Eilbeck, K.; Evangelista, C.; Gabrielian, A.E.; Gan, W.; Ge, W.; Gong, F.; Go, Z.; Guan, P.; Heiman, T. J.; Higgins, M. E.; Ji, R.R.; Ke, Z.; Ketchum, K.A.; Lai, Z.; Lei, Y.; Li, Z.; Li, J.; Liang, Y.; Lin, X.; Lu, F.; Merkulov, G. V.; Milshina, N4 Moore, H. M.; Naik, A. K.; Narayan, V. A.; Neelam, B.; Nusskern, D.; Rusch, D. B.; Salzberg, S.; Shao W.; Shue, B.; Sun, J.; Wang, Z.; Wang, A.; Wang. X.; Wang, J.; Wei, M.; Wides, R.; et al. (2001) The sequence of the human genome. Science 291, 1304-1351.
94. Watanabe, J.; Shimada, T.; Gillam, E. M.; Ikuta, T.; Suemasu, K.; Higashi, Y.; Gotoh, O. and Kawajiki, K. (2000) Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 10, 25-33.
95. Whitlock J, P.; Jr. (1999) Induction of cytochrome P4501A1. Annu. Rev. Pharmacol. Toxicol. 39, 103-125.
96. Willson, T. M. and Kliewer, S. A, (2002) PXR, CAR and drug metabolism. Nat. Rev. Drug Discov. 1, 259-266.
97. Yu, A.; Kneller, B. M.; Rettie, A. E. and Haining, R. L. (2002) Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J. Pharmacol. Exp. Ther. 303, 1291-1300.
98. Zheng, W.; Xie, D.W.; Jin, F.; Cheng, J.R.; Dai, Q.; Wen, W.Q.; Shu, X.O. and Gao, Y.T. (2000) Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 9, 147-150.